Trieu Vuong, the chairman and CEO of Oncotelic Therapeutics, Inc., has made notable stock purchases, acquiring a total of 1,356,990 shares in two separate transactions. This substantial investment, made from the open market, may indicate Vuong's confidence in the company's prospects.

On October 28, 2026, Vuong purchased 312,000 shares at a price of $0.0185 per share. The following day, he acquired an additional 1,044,990 shares for $0.017 each. Following these transactions, Vuong now holds a total of 95,481,309 shares directly.

Oncotelic Therapeutics operates in the pharmaceutical preparations sector, which is characterized by ongoing innovation and competition. Vuong's significant stock purchases could positively influence investor sentiment and highlight a commitment to the company's future.

Vuong's recent transactions are part of a series of filings that indicate his active involvement in the company's operations. The most recent filing was submitted on October 30, 2026, under accession number 0001493152-26-049370.

As of now, the filing does not specify any upcoming events or changes related to these transactions.

In addition to his direct stock purchases, Trieu Vuong has significant indirect ownership through Autotelic Inc., which holds 16,780,384 shares of Oncotelic Therapeutics, Inc. This indicates a broader commitment to the company's future, as Vuong's influence extends beyond his personal investments.

Furthermore, Vuong's spouse is reported to own 6,872,529 shares, suggesting that the family's overall stake in Oncotelic Therapeutics is substantial. This level of ownership could reflect a strong belief in the company's potential and strategic direction.

Vuong's transactions were conducted under Form 4, which is used to report changes in ownership of securities by insiders. The filing confirms that all transactions were executed in his individual capacity, highlighting his active role in the company's governance.

As of the filing date, there are no additional details regarding future plans or strategic initiatives from Oncotelic Therapeutics that might relate to these stock transactions.